Neuromuscular blocking agents (NMBAs) can be an effective modality to address
challenges that arise daily in the intensive care unit (ICU). These medications are often used …

Muscle weakness is common in the surgical intensive care unit (ICU). Low muscle mass at
ICU admission is a significant predictor of adverse outcomes. The consequences of ICU …

50th Anniversary Edition of the groundbreaking case-based pharmacotherapy text, now a
convenient two-volume set. Celebrating 50 years of excellence, Applied Therapeutics, 12th …

Objective: The relationship between neuromuscular blocking agents and neuromuscular
dysfunction acquired in critical illness remains unclear. We examined the association …

Pediatric acute respiratory distress syndrome (PARDS) is a significant cause of morbidity
and mortality in children. Children with PARDS often require intensive care admission and …

Neuromuscular blockings agents (NMBAs) have a controversial role in the ventilatory and
medical management of critical illness. The clinical concern surrounding NMBA-induced …

Objective: To review the theoretical benefits of airway pressure release ventilation (APRV),
summarize the evidence for its use in clinical practice, and discuss different titration …

Rationale: The neuromuscular blocking agent cisatracurium may improve mortality for
patients with moderate-to-severe acute respiratory distress syndrome (ARDS). Other …

Acute respiratory distress syndrome (ARDS) is an acute inflammatory process that impairs
the ability of the lungs to oxygenate thereby resulting in respiratory failure. Treatment of …

Objective: To review and evaluate neuromuscular blocking agents (NMBAs) in critically ill
patients with acute respiratory distress syndrome (ARDS). Data Sources: A literature search …